Abstract
High linear energy transfer (LET) radiotherapy has an excellent dose distribution and relative biological effectiveness (RBE). As the RBE of particle beams for therapy is important in terms of determining the dose prescription, we have to evaluate an accurate and reliable assessment method. Recently, several particle therapy facilities will open; however, the dose estimation is still not uniform. We have to confirm the quality assurance procedures among several facilities.
Excellent local effect has been already achieved by treatment of monotherapy of carbon ion radiotherapy. The efficacy of carbon ion radiotherapy has been confirmed by taking advantage of the physical and biological properties. In addition, we have to gain the higher survival rate for locally advanced tumor with potentially metastasis. This paper reviews briefly background of carbon ion radiotherapy, biophysical characters, biological characters, and several radiobiological factors. The potential benefit of multimodality treatment will be also discussed to further improve therapeutic outcomes.
Keywords: Radiation biology, high LET, carbon ion radiotherapy, biological quality assurance, multimodality therapy
Current Signal Transduction Therapy
Title: Signal Transduction and Heavy Ion Radiation Therapy: Biological Mechanisms, Biological Quality Assurance, and New Multimodality Approach
Volume: 5 Issue: 3
Author(s): Takeo Takahashi, Yukari Yoshida, Koichi Ando, Hidemasa Kawamura, Masahiko Okamoto, Jun-ichi Saitoh, Hitoshi Ishikawa, Takeshi Ebara, Yoshiyuki Suzuki, Tatsuya Ohno and Takashi Nakano
Affiliation:
Keywords: Radiation biology, high LET, carbon ion radiotherapy, biological quality assurance, multimodality therapy
Abstract: High linear energy transfer (LET) radiotherapy has an excellent dose distribution and relative biological effectiveness (RBE). As the RBE of particle beams for therapy is important in terms of determining the dose prescription, we have to evaluate an accurate and reliable assessment method. Recently, several particle therapy facilities will open; however, the dose estimation is still not uniform. We have to confirm the quality assurance procedures among several facilities.
Excellent local effect has been already achieved by treatment of monotherapy of carbon ion radiotherapy. The efficacy of carbon ion radiotherapy has been confirmed by taking advantage of the physical and biological properties. In addition, we have to gain the higher survival rate for locally advanced tumor with potentially metastasis. This paper reviews briefly background of carbon ion radiotherapy, biophysical characters, biological characters, and several radiobiological factors. The potential benefit of multimodality treatment will be also discussed to further improve therapeutic outcomes.
Export Options
About this article
Cite this article as:
Takahashi Takeo, Yoshida Yukari, Ando Koichi, Kawamura Hidemasa, Okamoto Masahiko, Saitoh Jun-ichi, Ishikawa Hitoshi, Ebara Takeshi, Suzuki Yoshiyuki, Ohno Tatsuya and Nakano Takashi, Signal Transduction and Heavy Ion Radiation Therapy: Biological Mechanisms, Biological Quality Assurance, and New Multimodality Approach, Current Signal Transduction Therapy 2010; 5 (3) . https://dx.doi.org/10.2174/157436210791920238
DOI https://dx.doi.org/10.2174/157436210791920238 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gene Expression Abnormalities in Thymoma
Current Pharmacogenomics Modular Protein Engineering in Emerging Cancer Therapies
Current Pharmaceutical Design Targeting Pattern Recognition Receptors (PRRs) in Nano- Adjuvants: Current Perspectives
Current Bionanotechnology (Discontinued) From HPV Infection to Oncogenesis: A Brief Review of the Complex Immunobiological Events
Current Cancer Therapy Reviews In vivo Monitoring of Oxygen Levels in Human Brain Tumor Between Fractionated Radiotherapy Using Oxygen-enhanced MR Imaging
Current Medical Imaging The Cone Beam O-Arm Imaging System: Radiation Dose, Image Quality, and Clinical Applications
Recent Patents on Medical Imaging Thiosemicarbazone-Pt(II) Complex Causes a Growth Inhibitory Effect on Human Mesenchymal Stem Cells
Medicinal Chemistry Tubulin Maytansine Site Binding Ligands and their Applications as MTAs and ADCs for Cancer Therapy
Current Medicinal Chemistry Management of Glioblastoma Multiforme by Phytochemicals: Applications of Nanoparticle-Based Targeted Drug Delivery System
Current Drug Targets The Significance of Transferrin Receptors in Oncology: the Development of Functional Nano-based Drug Delivery Systems
Current Drug Delivery Effect of DNA Repair Deficiencies on the Cytotoxicity of Drugs Used in Cancer Therapy - A Review
Current Medicinal Chemistry Platelet Biomarkers in Tumor Growth
Current Proteomics Contribution of Catecholamine Reactive Intermediates and Oxidative Stress to the Pathologic Features of Heart Diseases
Current Medicinal Chemistry Anticancer Antioxidant Regulatory Functions of Phytochemicals
Current Medicinal Chemistry Genistein Induces Alterations of Epigenetic Modulatory Signatures in Human Cervical Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Cervical Cancer and Human Papillomaviruses: Inactivation of Retinoblastoma and Other Tumor Suppressor Pathways
Current Molecular Medicine Role of mTOR Signaling in Tumor Cell Motility, Invasion and Metastasis
Current Protein & Peptide Science Manipulation of Glycolysis in Malignant Tumors: Fantasy or Therapy?
Current Medicinal Chemistry Oncolytic Viruses for Induction of Anti-Tumor Immunity
Current Pharmaceutical Biotechnology FOXO and FOXM1 in Cancer: The FOXO-FOXM1 Axis Shapes the Outcome of Cancer Chemotherapy
Current Drug Targets